Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: indacaterol and glycopyrronium (QVA149)
Drug: fluticasone/salmeterol
Drug: Placebo to fluticasone/salmeterol
Drug: Placebo to indacaterol and glycopyrronium (QVA149)

First Posted Date: 2011-03-15

Last Posted Date: 2013-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 523

Registration Number: NCT01315249

Locations: 🇪🇸
Novartis Investigative Site, Valladolid, Spain

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukaemia

Interventions: Drug: Physicians' Choice
Drug: Ofatumumab

First Posted Date: 2011-03-14

Last Posted Date: 2018-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT01313689

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2011-03-08

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 447

Registration Number: NCT01310166

Locations: 🇩🇪
Novartis Investigative Site, Wolfenbüttel, Germany

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Vildagliptin (LAF237)
Drug: Voglibose
Drug: Vildagliptin and Voglibose

First Posted Date: 2011-03-07

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01309698

Locations: 🇯🇵
Novartis Investigative Site, Tokyo, Japan

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

Phase 2

Terminated

Conditions: Non-diabetic Nephropathy

Interventions: Drug: Aliskiren
Drug: Placebo to Aliskiren
Drug: Hydrochlorothiazide (HCTZ)
Drug: Placebo to Hydrochlorothiazide (HCTZ)
Drug: Ramipril

First Posted Date: 2011-02-24

Last Posted Date: 2013-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT01302899

Locations: 🇳🇱
Novartis Investigative Site, Leeuwarden, Netherlands

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: BHQ880

First Posted Date: 2011-02-24

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT01302886

Locations: 🇺🇸
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States
🇺🇸
Hackensack University Medical Center Multiple Myeloma Division, Hackensack, New Jersey, United States
🇺🇸
Dana Farber Cancer Institute DFCI (2), Boston, Massachusetts, United States

and more 8 locations

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Phase 3

Completed

Conditions: Neonatal Onset Multisystem Inflammatory Disease
Familial Cold Autoinflammatory Syndrome
Cryopyrin-associated Periodic Syndromes
Muckle-Wells Syndrome

Interventions: Drug: ACZ885

First Posted Date: 2011-02-24

Last Posted Date: 2017-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01302860

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Canakinumab in Patients With Active Hyper-IgD Syndrome

Phase 2

Completed

Conditions: Mevalonate Kinase Deficiency

Interventions: Drug: Canakinumab

First Posted Date: 2011-02-24

Last Posted Date: 2015-11-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT01303380

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Study of BGG492 in Patients With Chronic Subjective Tinnitus

Phase 2

Completed

Conditions: Chronic Subjective Tinnitus

Interventions: Drug: BGG492A

First Posted Date: 2011-02-24

Last Posted Date: 2017-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT01302873

Locations: 🇳🇱
Novartis Investigative Site, Groningen, Netherlands

Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms

Completed

Conditions: GI Symptoms Severity
Kidney Transplantation

First Posted Date: 2011-02-21

Last Posted Date: 2016-03-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 101

Registration Number: NCT01300416

Locations: 🇲🇾
Hospital Pulau Pinang, Pulau Pinang, Malaysia
🇲🇾
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
🇲🇾
Hospital Tengku Ampuan Afzan, Kuantan, Malaysia

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy